Navigation Links
Trillium Strengthens its Board of Directors
Date:11/5/2008

TORONTO, Nov. 5 /PRNewswire/ - Trillium Therapeutics Inc., a privately held biopharmaceutical company, announced today that industry veterans Dr. Michael Berendt and Dr. John Dietrich have joined its Board as independent directors. Trillium Chairman Dr. Michael Moore commented: "It is a great pleasure to welcome these two experienced biotech executives to the Board where they will enhance our capabilities in strategic planning and product development. Their appointments are commensurate with completion of an internal financing round of $12 million and the entry into clinical development of Trillium's lead product, TTI-1612."

About Dr. Michael Berendt: Dr. Berendt is the President and CEO of Aegera Therapeutics. Prior to joining Aegera, he served as managing director of Research Corporation Technologies (RCT), a US-based technology investment and management company, and AEA Investors Inc., where focusing on growth equity investments in life sciences companies. Previously Dr. Berendt was Senior Vice President of Research for the Pharmaceutical Division of Bayer Corporation. He is currently a director of Waters Corporation and has served on the board of directors of numerous other life sciences companies. Dr. Berendt received a doctoral degree in medical microbiology and immunology from Hahnemann University.

About Dr. John Dietrich: Dr. Dietrich joined Ventrus Biosciences in April 2007, where he currently serves as Vice President, Clinical Operations. From 2000 to 2007, Dr. Dietrich was Vice President of Research and Development at VIVUS, Inc, prior to which he was Vice President of Research and Development at Cellegy Pharmaceuticals. Dr. Dietrich served as Senior Vice President of Research and Development at Allelix Biopharmaceuticals between 1991 and 1999. In this position, he was responsible for all aspects of drug discovery and development. Before joining Allelix, he held management positions at Chemex and Revlon Health Care. Dr. Dietrich received his PhD in pharmacology from the University of North Carolina at Chapel Hill.

About Trillium: Trillium Therapeutics Inc. is a private biopharmaceutical company specializing in innovative therapies of immune-mediated conditions, such as autoimmune and inflammatory disorders, as well as cancer. The company's lead program, a recombinant heparin-binding epidermal growth factor-like growth factor (HB-EGF), is being developed for the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. IND filing on the lead product, TTI-1612, was submitted to the FDA in October 2008. In addition, Trillium has two preclinical programs targeting the CD200 immunoregulatory axis; a CD200-specific monoclonal antibody for the treatment of cancer, and a CD200Fc fusion protein for the treatment of autoimmune and inflammatory diseases. The company has a broad network of external academic and industry R&D collaborations, including several license agreements with major US biotechnology companies. To date the Company has raised approximately $25 million in investment capital through Vengrowth Private Equity Partners, Canadian Medical Discoveries Fund (CMDF) and BDC Venture Capital.


'/>"/>
SOURCE Trillium Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway
2. Medpace Strengthens Presence in Central Europe
3. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
4. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
5. DuPont Joint Venture with Chinese Biotech Firm Strengthens Gene Discovery Research Efforts
6. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
7. Anavex strengthens Board of Directors
8. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
9. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
10. JobLoft.com Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition
11. BioSpace.com Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
Breaking Biology Technology:
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
Breaking Biology News(10 mins):